Prostate cancer is a malignancy in the prostate gland, which is located below the bladder and in front of the rectum in males. Worldwide, about 1.4 million men were diagnosed with prostate cancer in 2020 (Wang et al., 2022). In the US, prostate cancer is the most common cancer in men after skin cancer, and it is the third most common cause of cancer death in men (Siegel et al., 2020). Approximately one in seven American men are diagnosed with prostate cancer in their lifetime. However, most are diagnosed after age 65 years, and patients often live long enough that they die of other causes (National Cancer Institute, 2024). Homologous recombination deficiency (HRD) mutations, which affect the DNA repair pathway, increase a man’s risk of contracting prostate cancer (Heeke et al., 2018a, 2018b). Almost all prostate cancers are adenocarcinomas, a type of cancer that develops in gland cells. Most prostate cancers are asymptomatic and grow very slowly. In advanced stages of prostate cancer, the malignancy has spread to other organs such as seminal vesicles, lymph nodes, or bones. When a tumor fails to respond to androgen deprivation therapy, it is referred to as castration-resistant prostate cancer (CRPC) (National Cancer Institute, 2024).
Scope
- This report provides an overview of the risk factors, comorbidities, and global and historical trends for prostate cancer in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and China). It includes a 10-year epidemiological forecast for diagnosed incident cases of prostate cancer in men segmented by age (beginning at ages 30 years) and stage at diagnosis (stage I, IIA, IIB, III, IV-M0, and IV-M1). Additionally, this report forecasts five-year diagnosed prevalent cases of prostate cancer segmented by stage (stage I-II, III, and IV-M0 and IV-M1), progressed cases (local and regional to stage IV-M0 and IV-M1), Gleason scores (2-10), metastatic and non-metastatic CRPC cases, and DNA repair mutations in metastatic CRPC (mCRPC) cases. Finally, the epidemiology model corresponding to this report presents prostate cancer diagnosed incident cases by Gleason scores (2-10).
Reasons to Buy
The Prostate Cancer Epidemiology series will allow you to:
- Develop business strategies by understanding the trends shaping and driving the global prostate cancer markets.
- Quantify patient populations in the global prostate cancer markets to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the groups that present the best opportunities for prostate cancer therapeutics in each of the markets covered.
- Understand magnitude of the prostate cancer population by age, staging, progression and biomarkers.
Table of Contents
- About the Analyst
1 Prostate cancer: Executive Summary
2 Epidemiology
3 Appendix
List of Tables
List of Figures
